Prenetics Global vs Zhengye Biotechnology
PRE and ZYBT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRE and ZYBT compare
Prenetics Global grew revenue faster over the last twelve months (480% versus −37.6% for Zhengye Biotechnology).
Prenetics Global keeps more of each dollar of sales as profit, with a net margin of −40.8% compared with −60.0% at Zhengye Biotechnology.
Prenetics Global scores higher on the StockData Score (10 against 4 for Zhengye Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRE | ZYBT |
|---|---|---|
| Size and price | ||
| Share price | $17.64 | $1.52 |
| Change, 1 year | 48.4% | −26.6% |
| Change, 5 years | −88.1% | – |
| Beta (5Y) | 0.60 | −0.35 |
| Employees | 98 | 51 |
| StockData Score | ||
| Total score | 10 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 480% (better) | −37.6% |
| Revenue growth, 5Y average | 7.2% | – |
| Net income growth (TTM) | – | −717% |
| Profitability | ||
| Gross margin | 52.8% (better) | 20.5% |
| Operating margin | −48.1% (better) | −60.6% |
| Net margin | −40.8% (better) | −60.0% |
| FCF margin | −23.8% | 10.6% (better) |
| Return on equity | −23.1% (better) | −26.1% |
| Return on invested capital | −29.0% | −18.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.26 (better) |
| Interest coverage | – | −20.7× |
| Current ratio | 2.97 (better) | 1.14 |
| Piotroski F-score | 5 (better) | 3 |
| Ownership | ||
| Held by insiders | 14.2% | 90.7% |
| Insider net buying, 12 months | $1000K | – |
Go deeper
- PRE stock overview
- PRE income statement
- PRE valuation and score
- ZYBT stock overview
- ZYBT income statement
- ZYBT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.